Last reviewed · How we verify

NCT07105358: VIBRANT

Visual Plasticity Following Brain Lesions

Recruiting now NA Last updated 5 August 2025
What this trial tests

NA trial testing transcranial random noise stimulation (tRNS) in Visual Field Defect in 30 participants. Currently enrolling.

Timeline
17 July 2025
Primary endpoint
30 June 2028
30 June 2028

Quick facts

Lead sponsorGeorgetown University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposetreatment
Enrollment30
Start date17 July 2025
Primary completion30 June 2028
Estimated completion30 June 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Georgetown University

Who can join

18 and older, any sex, with Visual Field Defect or Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The VIBRANT (Vision Improvement through Behavioral Rehabilitation And Neuroplasticity Training) study is a prospective, double-blind, crossover design (within-subject) in participants with homonymous hemianopia-a type of visual field loss resulting from damage to the post-chiasmatic visual pathways. It aims to investigate whether transcranial random noise stimulation (tRNS) combined with perceptual learning-based training has potential for improving visual impairments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of transcranial random noise stimulation (tRNS)

Trials testing the same drug.

Other recruiting trials for Visual Field Defect

Currently open trials in the same condition.

Other Georgetown University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07105358.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing